Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study reveal encouraging signals in acute MS lesions, suggesting that the novel imaging technique may be able to distinguish between demyelinated nerve fibers that could still recover and those that have suffered permanent damage. This distinction is critical for accurately measuring myelin loss and repair, which could transform how MS progression is monitored and treated.
The imaging technique is directly relevant to Lucid-MS, the company's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. By pairing a more precise imaging tool with a drug candidate aimed at the underlying cause of MS, Quantum BioPharma is positioning itself at the forefront of MS research. Reaching the enrollment midpoint with promising early data suggests that the science is holding up under real clinical conditions, a positive sign for the ongoing study and the potential future of Lucid-MS.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS. The company also invented unbuzzd, a product aimed at reducing alcohol cravings, and spun out its OTC version to Unbuzzd Wellness Inc., while retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments from sales.
The implications of this imaging advance are significant. If the technique proves effective in larger trials, it could provide a non-invasive way to monitor MS activity and treatment response, enabling more personalized and timely interventions. For Quantum BioPharma, this could accelerate the clinical development of Lucid-MS, offering hope to millions of MS patients worldwide.
For more information about Quantum BioPharma, visit the company's newsroom at https://nnw.fm/QNTM.
